Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1979 1
1985 2
1987 1
1991 1
1995 2
1997 1
1999 2
2001 1
2002 1
2003 2
2005 2
2006 1
2007 1
2009 2
2010 2
2011 4
2012 2
2013 3
2014 4
2016 4
2017 6
2018 4
2019 7
2020 10
2021 9
2022 12
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update.
Sarin SK, Choudhury A, Sharma MK, Maiwall R, Al Mahtab M, Rahman S, Saigal S, Saraf N, Soin AS, Devarbhavi H, Kim DJ, Dhiman RK, Duseja A, Taneja S, Eapen CE, Goel A, Ning Q, Chen T, Ma K, Duan Z, Yu C, Treeprasertsuk S, Hamid SS, Butt AS, Jafri W, Shukla A, Saraswat V, Tan SS, Sood A, Midha V, Goyal O, Ghazinyan H, Arora A, Hu J, Sahu M, Rao PN, Lee GH, Lim SG, Lesmana LA, Lesmana CR, Shah S, Prasad VGM, Payawal DA, Abbas Z, Dokmeci AK, Sollano JD, Carpio G, Shresta A, Lau GK, Fazal Karim M, Shiha G, Gani R, Kalista KF, Yuen MF, Alam S, Khanna R, Sood V, Lal BB, Pamecha V, Jindal A, Rajan V, Arora V, Yokosuka O, Niriella MA, Li H, Qi X, Tanaka A, Mochida S, Chaudhuri DR, Gane E, Win KM, Chen WT, Rela M, Kapoor D, Rastogi A, Kale P, Rastogi A, Sharma CB, Bajpai M, Singh V, Premkumar M, Maharashi S, Olithselvan A, Philips CA, Srivastava A, Yachha SK, Wani ZA, Thapa BR, Saraya A, Shalimar, Kumar A, Wadhawan M, Gupta S, Madan K, Sakhuja P, Vij V, Sharma BC, Garg H, Garg V, Kalal C, Anand L, Vyas T, Mathur RP, Kumar G, Jain P, Pasupuleti SSR, Chawla YK, Chowdhury A, Alam S, Song DS, Yang JM, Yoon EL; APASL ACLF Research Consortium (AARC) for APASL ACLF working Party.. Sarin SK, et al. Hepatol Int. 2019 Jul;13(4):353-390. doi: 10.1007/s12072-019-09946-3. Epub 2019 Jun 6. Hepatol Int. 2019. PMID: 31172417 Free PMC article.
The first consensus report of the working party of the Asian Pacific Association for the Study of the Liver (APASL) set up in 2004 on acute-on-chronic liver failure (ACLF) was published in 2009. ...After detailed deliberations and data analysis, the original definit …
The first consensus report of the working party of the Asian Pacific Association for the Study of the Liver (APASL) set up in 2004 on …
Psoriasis and comorbid diseases: Implications for management.
Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Takeshita J, et al. J Am Acad Dermatol. 2017 Mar;76(3):393-403. doi: 10.1016/j.jaad.2016.07.065. J Am Acad Dermatol. 2017. PMID: 28212760 Free PMC article. Review.
Recognizing the comorbid disease burden of psoriasis is essential for ensuring comprehensive care of patients with psoriasis. The clinical implications of the comorbid diseases that are associated with psoriasis and recommendations for clinical management are reviewed in t …
Recognizing the comorbid disease burden of psoriasis is essential for ensuring comprehensive care of patients with psoriasis. The cli …
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.
Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Beckman JA, Bhatt DL, Bloomgarden ZT, Bozkurt B, Budoff MJ, Butler J, Dagogo-Jack S, de Boer IH, DeFronzo RA, Eckel RH, Einhorn D, Fonseca VA, Green JB, Grunberger G, Guerin C, Inzucchi SE, Jellinger PS, Kosiborod MN, Kushner P, Lepor N, Mende CW, Michos ED, Plutzky J, Taub PR, Umpierrez GE, Vaduganathan M, Weir MR. Handelsman Y, et al. J Diabetes Complications. 2022 Feb;36(2):108101. doi: 10.1016/j.jdiacomp.2021.108101. Epub 2021 Dec 7. J Diabetes Complications. 2022. PMID: 34922811 Free PMC article. Review.
The ultimate goal for these recommendations is to be comprehensive yet succinct and easy to follow by the nonexpert-whether a specialist or a primary care clinician. To meet this need, we formed a volunteer task force comprising leading cardiologists, nephrologists, endocr …
The ultimate goal for these recommendations is to be comprehensive yet succinct and easy to follow by the nonexpert-whether a specialist or …
Therapeutic opportunities for the treatment of NASH with genetically validated targets.
Lindén D, Romeo S. Lindén D, et al. J Hepatol. 2023 Oct;79(4):1056-1064. doi: 10.1016/j.jhep.2023.05.007. Epub 2023 May 17. J Hepatol. 2023. PMID: 37207913 Review.
The identification of genetic variants associated with fatty liver disease (FLD) from genome-wide association studies started in 2008 when single nucleotide polymorphisms in PNPLA3, the gene encoding patatin-like phospholipase domain-containing 3, were found to be a …
The identification of genetic variants associated with fatty liver disease (FLD) from genome-wide association studies started …
The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management.
Xu B, Li S, Kang B, Zhou J. Xu B, et al. Cardiovasc Diabetol. 2022 May 25;21(1):83. doi: 10.1186/s12933-022-01512-w. Cardiovasc Diabetol. 2022. PMID: 35614469 Free PMC article. Review.
SGLT2 inhibitors increase urinary glucose excretion via inhibiting SGLT2 to decrease renal reabsorption of filtered glucose and reduce the renal threshold for glucose. ...SGLT2 inhibitors are expected to be an effective treatment for T2DM patients with non alcoholic …
SGLT2 inhibitors increase urinary glucose excretion via inhibiting SGLT2 to decrease renal reabsorption of filtered glucose and reduc …
Management of Metabolic-Associated Fatty Liver Disease.
Venkatesan K, Haroon NN. Venkatesan K, et al. Endocrinol Metab Clin North Am. 2023 Sep;52(3):547-557. doi: 10.1016/j.ecl.2023.02.002. Epub 2023 Mar 21. Endocrinol Metab Clin North Am. 2023. PMID: 37495344 Review.
Metabolic-associated fatty liver disease (MAFLD), previously known as nonalcoholic fatty liver disease (NAFLD), is the most common cause of liver disease in the world. Its prevalence is over 30% and is becoming the most common cause of liver …
Metabolic-associated fatty liver disease (MAFLD), previously known as nonalcoholic fatty liver disease (NAFLD), …
Polyagonists in Type 2 Diabetes Management.
Dissanayake HA, Somasundaram NP. Dissanayake HA, et al. Curr Diab Rep. 2024 Jan;24(1):1-12. doi: 10.1007/s11892-023-01530-2. Epub 2023 Dec 27. Curr Diab Rep. 2024. PMID: 38150106 Review.
RECENT FINDINGS: Several dual- and triple-agonists targeting different pathogenic pathways of type 2 diabetes have entered clinical trials and have led to significant improvements in glycaemia, body weight, fatty liver, and cardio-renal risk factors, with var …
RECENT FINDINGS: Several dual- and triple-agonists targeting different pathogenic pathways of type 2 diabetes have entered clinical trials a …
Consensus clinical management guidelines for Alstrom syndrome.
Tahani N, Maffei P, Dollfus H, Paisey R, Valverde D, Milan G, Han JC, Favaretto F, Madathil SC, Dawson C, Armstrong MJ, Warfield AT, Düzenli S, Francomano CA, Gunay-Aygun M, Dassie F, Marion V, Valenti M, Leeson-Beevers K, Chivers A, Steeds R, Barrett T, Geberhiwot T. Tahani N, et al. Orphanet J Rare Dis. 2020 Sep 21;15(1):253. doi: 10.1186/s13023-020-01468-8. Orphanet J Rare Dis. 2020. PMID: 32958032 Free PMC article.
ALMS is a multisystem, progressive disease characterised by visual disturbance, hearing impairment, cardiomyopathy, childhood obesity, extreme insulin resistance, accelerated non-alcoholic fatty liver disease (NAFLD), renal dysfunction, respiratory disease, e …
ALMS is a multisystem, progressive disease characterised by visual disturbance, hearing impairment, cardiomyopathy, childhood obesity, extre …
Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.
Kostapanos MS, Rizos CV, Elisaf MS. Kostapanos MS, et al. Drug Saf. 2014 Jul;37(7):481-500. doi: 10.1007/s40264-014-0169-4. Drug Saf. 2014. PMID: 24788803 Review.
It was estimated that rosuvastatin-associated absolute hazards of muscle-, liver- and renal-related adverse effects are lower than the corresponding vascular benefits in moderate vascular risk individuals. However, these data are subject to biases and need confirmat …
It was estimated that rosuvastatin-associated absolute hazards of muscle-, liver- and renal-related adverse effects are lower …
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease.
Wijarnpreecha K, Aby ES, Ahmed A, Kim D. Wijarnpreecha K, et al. Clin Mol Hepatol. 2021 Apr;27(2):221-235. doi: 10.3350/cmh.2020.0239. Epub 2020 Dec 3. Clin Mol Hepatol. 2021. PMID: 33317243 Free PMC article. Review.
Nonalcoholic fatty liver disease (NAFLD) is a multisystemic disease and a rapidly growing cause of chronic liver disease in children and adults worldwide. ...The leading cause of death in NAFLD is primarily from CVD, followed by liver-related mortality …
Nonalcoholic fatty liver disease (NAFLD) is a multisystemic disease and a rapidly growing cause of chronic liver diseas …
91 results